ELIZABETH M COTTINGHAM, MD
Psychiatric at Hollister St, Cincinnati, OH
License number
Ohio 35072493
Category
Psychiatric
Type
Psychiatry
License number
Ohio 35072493
Category
Psychiatric
Type
Child & Adolescent Psychiatry
Address
Address
58 E Hollister St, Cincinnati, OH 45219
Phone
(513) 721-1737
(513) 287-7465 (Fax)
(513) 287-7465 (Fax)
Personal information
See more information about ELIZABETH M COTTINGHAM at radaris.comName
Address
Phone
300 Warren Ave, Cincinnati, OH 45220
58 Hollister St, Cincinnati, OH 45219
300 Warren Ave, Cincinnati, OH 45220
Professional information
Elizabeth M Cottingham, Cincinnati OH
Specialties:
Psychiatrist
Address:
58 E Hollister St, Cincinnati, OH 45219
Board certifications:
American Board of Psychiatry and Neurology Certification in Psychiatry (Psychiatry and Neurology), American Board of Psychiatry and Neurology Sub-certificate in Child and Adolescent Psychiatry (Psychiatry and Neurology)
Dr. Elizabeth M Cottingham, Cincinnati OH - MD (Doctor of Medicine)
Specialties:
Child & Adolescent Psychiatry
Address:
Sachs Dubin Fox Rowe Mds
58 E Hollister St, Cincinnati 45219
(513) 721-1737 (Phone)
58 E Hollister St, Cincinnati 45219
(513) 721-1737 (Phone)
Certifications:
Child & Adolescent Psychiatry, 2007, Psychiatry, 2006
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of Louisville School Of Medicine
Graduated: 1991
Med University Sc Med Center
University Louisville School Of Med
University Of Louisville School Of Medicine
Graduated: 1991
Med University Sc Med Center
University Louisville School Of Med
Use Of Metformin To Counteract Weight Gain Associated With Valproate And Other Psychotropic Medications
US Patent:
6194466, Feb 27, 2001
Filed:
Oct 12, 1999
Appl. No.:
9/416330
Inventors:
Elizabeth Marie Cottingham - Cincinnati OH
John Ainslie Morrison - Cincinnati OH
John Ainslie Morrison - Cincinnati OH
International Classification:
A61K 31155, A61K 3119
US Classification:
514635
Abstract:
A method for minimizing the weight gain side effect associated with Valproate treatment is disclosed. In this method, Metformin, a biguanide compound, is concurrently administered to a patient taking the Valproate therapy. A pharmaceutical composition containing the combination of Valproate and Metformin is also disclosed.